An Opioid Combo Falls Short in Depression
The Carlat Psychiatry Report, Volume 17, Number 2, February 2019
Chris Aiken, MD
Opioids have a bad name these days. But let’s not forget that they were once considered a first-line treatment for depression before the discovery of MAOIs and tricyclics in the 1950s. That history has been revived recently by buprenorphine, a partial opioid agonist that was fast-tracked by the FDA for treatment-resistant depression.